Please login to the form below

Not currently logged in
Email:
Password:

EGFR

This page shows the latest EGFR news and features for those working in and with pharma, biotech and healthcare.

Eli Lilly, Innovent showcase Tyvyt data in first-line NSCLC

Eli Lilly, Innovent showcase Tyvyt data in first-line NSCLC

In the 397-patient ORIENT-11 trial, Tyvyt (sintilimab) and Alimta (pemetrexed) were administered in combination with platinum chemotherapy as a first-line treatment for advanced or recurrent NSCLC without EGFR

Latest news

More from news
Approximately 6 fully matching, plus 162 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    Tagrisso’s growth as it moves earlier in the treatment pathway for EGFR-positive non-small lung cancer (NSCLC) and launches in new markets like China, plus possible label extensions for

  • Encouraging signs in biomarker R&D Encouraging signs in biomarker R&D

    Similarly, in other cancers, EGFR mutations, NTRK fusions and ALK fusions are all used as biomarkers because they indicate patients are likely to respond well to targeted therapies. ... The questions being asked are, what does an individual’s

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    lung cancer NSCLC patients with low PD-L1 expression (1%, also without EGFR or ALK mutations) – a group that was once thought unlikely to benefit from these drugs.

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    There is a good reason why Tagrisso was chosen for the fast track – the drug is for patients with epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung ... The EGFR mutation is particularly prevalent in Asian populations

  • 30 Women Leaders in UK Healthcare 30 Women Leaders in UK Healthcare

    She played a key role in the development and approval of Tagrisso, AstraZeneca’s next-generation EGFR-targeting lung cancer treatment that is proving a major advance on existing treatments, and

More from intelligence
Approximately 0 fully matching, plus 13 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics